➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Moodys
Harvard Business School
Mallinckrodt
McKesson

Last Updated: August 12, 2020

DrugPatentWatch Database Preview

Lanreotide acetate - Generic Drug Details

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

What are the generic drug sources for lanreotide acetate and what is the scope of patent protection?

Lanreotide acetate is the generic ingredient in one branded drug marketed by Ipsen Pharma and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Lanreotide acetate has seventy-one patent family members in seventeen countries.

There are three drug master file entries for lanreotide acetate. One supplier is listed for this compound.

Summary for lanreotide acetate
International Patents:71
US Patents:1
Tradenames:1
Applicants:1
NDAs:1
Drug Master File Entries: 3
Suppliers / Packagers: 1
Bulk Api Vendors: 46
Clinical Trials: 3
Patent Applications: 5,653
DailyMed Link:lanreotide acetate at DailyMed
Recent Clinical Trials for lanreotide acetate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
IpsenPhase 1/Phase 2
IpsenPhase 3
IpsenPhase 4

See all lanreotide acetate clinical trials

Pharmacology for lanreotide acetate

US Patents and Regulatory Information for lanreotide acetate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ipsen Pharma SOMATULINE DEPOT lanreotide acetate SOLUTION;SUBCUTANEOUS 022074-002 Aug 30, 2007 RX Yes Yes   Start Trial   Start Trial   Start Trial
Ipsen Pharma SOMATULINE DEPOT lanreotide acetate SOLUTION;SUBCUTANEOUS 022074-001 Aug 30, 2007 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
Ipsen Pharma SOMATULINE DEPOT lanreotide acetate SOLUTION;SUBCUTANEOUS 022074-003 Aug 30, 2007 RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for lanreotide acetate

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ipsen Pharma SOMATULINE DEPOT lanreotide acetate SOLUTION;SUBCUTANEOUS 022074-001 Aug 30, 2007   Start Trial   Start Trial
Ipsen Pharma SOMATULINE DEPOT lanreotide acetate SOLUTION;SUBCUTANEOUS 022074-003 Aug 30, 2007   Start Trial   Start Trial
Ipsen Pharma SOMATULINE DEPOT lanreotide acetate SOLUTION;SUBCUTANEOUS 022074-002 Aug 30, 2007   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
Merck
Johnson and Johnson
Mallinckrodt
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.